JP2013538856A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538856A5 JP2013538856A5 JP2013531769A JP2013531769A JP2013538856A5 JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5 JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- pharmaceutical composition
- composition according
- pegylated
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38900910P | 2010-10-01 | 2010-10-01 | |
| US61/389,009 | 2010-10-01 | ||
| PCT/US2011/053681 WO2012044684A2 (en) | 2010-10-01 | 2011-09-28 | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016181104A Division JP2017025086A (ja) | 2010-10-01 | 2016-09-16 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538856A JP2013538856A (ja) | 2013-10-17 |
| JP2013538856A5 true JP2013538856A5 (enExample) | 2014-11-13 |
Family
ID=45890011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013531769A Pending JP2013538856A (ja) | 2010-10-01 | 2011-09-28 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
| JP2016181104A Pending JP2017025086A (ja) | 2010-10-01 | 2016-09-16 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016181104A Pending JP2017025086A (ja) | 2010-10-01 | 2016-09-16 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120082647A1 (enExample) |
| EP (1) | EP2621516B1 (enExample) |
| JP (2) | JP2013538856A (enExample) |
| AU (2) | AU2011308906B2 (enExample) |
| CA (1) | CA2813304A1 (enExample) |
| ES (1) | ES2587837T3 (enExample) |
| MX (1) | MX2013003599A (enExample) |
| NZ (2) | NZ608630A (enExample) |
| WO (1) | WO2012044684A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| US20150366944A1 (en) | 2013-02-20 | 2015-12-24 | Yeda Research And Development Co. Ltd. | Interferon treatment targeting mutant p53 expressing cells |
| WO2014130811A1 (en) * | 2013-02-22 | 2014-08-28 | Biogen Idec Ma Inc | Interferon beta formulation |
| AU2015239104B2 (en) | 2014-04-04 | 2018-12-20 | Ares Trading S.A. | Novel IFN beta protein analogs |
| ES2880835T3 (es) * | 2014-11-19 | 2021-11-25 | Nat Defense Medical Center | Composición farmacéutica para el tratamiento del cáncer y biomarcador para el cribado de fármacos |
| KR102666000B1 (ko) * | 2016-07-29 | 2024-05-14 | 서울대학교 산학협력단 | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 |
| CN112569359A (zh) * | 2019-09-30 | 2021-03-30 | 上海生物制品研究所有限责任公司 | 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用 |
| CN112569358B (zh) * | 2019-09-30 | 2022-06-28 | 上海生物制品研究所有限责任公司 | 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH08505395A (ja) | 1993-01-06 | 1996-06-11 | キナートン リミティド | 生物分解性ポリエステルと生物活性ポリペプチドのイオン分子結合体 |
| DK1656952T3 (da) * | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
| AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| CN102319437B (zh) * | 2002-12-26 | 2017-10-13 | 山景医药公司 | 具有增强的生物学效用的干扰素‑β的聚合物缀合物 |
| PE20071042A1 (es) * | 2005-11-04 | 2007-10-12 | Wyeth Corp | Producto farmaceutico que comprende temsirolimus y malato de sunitinib |
| WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
| AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
-
2011
- 2011-09-28 MX MX2013003599A patent/MX2013003599A/es unknown
- 2011-09-28 EP EP11829825.6A patent/EP2621516B1/en not_active Not-in-force
- 2011-09-28 ES ES11829825.6T patent/ES2587837T3/es active Active
- 2011-09-28 NZ NZ608630A patent/NZ608630A/en not_active IP Right Cessation
- 2011-09-28 AU AU2011308906A patent/AU2011308906B2/en not_active Ceased
- 2011-09-28 WO PCT/US2011/053681 patent/WO2012044684A2/en not_active Ceased
- 2011-09-28 NZ NZ705124A patent/NZ705124A/en not_active IP Right Cessation
- 2011-09-28 US US13/247,556 patent/US20120082647A1/en not_active Abandoned
- 2011-09-28 JP JP2013531769A patent/JP2013538856A/ja active Pending
- 2011-09-28 CA CA2813304A patent/CA2813304A1/en not_active Abandoned
-
2015
- 2015-10-15 US US14/884,530 patent/US20160228513A1/en not_active Abandoned
-
2016
- 2016-09-15 AU AU2016228234A patent/AU2016228234A1/en not_active Abandoned
- 2016-09-16 JP JP2016181104A patent/JP2017025086A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077356A (es) | Forma termodinámicamente estable de una sal tosilato | |
| JP2012502885A5 (enExample) | ||
| MX2009002642A (es) | 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluoro fenoxi]-n-metilpiridina-2-carboxamida monohidrato. | |
| UA100966C2 (ru) | Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей | |
| BR112013026706A2 (pt) | composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico | |
| JP2012520883A5 (enExample) | ||
| JP2011510093A5 (ja) | 口腔ケア製品ならびにその使用および製造の方法 | |
| JP2009517473A5 (enExample) | ||
| PT2684877T (pt) | Sal farmaceuticamente aceitável de (e)-n-[4-[[3-cloro-4-(2- piridilmetoxi)fenil]amino]-3-ciano-7-etoxi-6-quinolil]-3-[(2r)-1-metilpirrolidin-2-il]prop-2-enamida, seu método de preparação e a sua utilização clínica | |
| EP2724707A3 (de) | Haarpflegemittel mit Antischuppenwirkstoffen und einem kationischen Keratinhydrolysat | |
| NZ596863A (en) | Alkanoylamino benzamide aniline hdac inhibitor compounds | |
| TWI351950B (en) | Use of (halobenzyloxy) benzylamino-propanamides fo | |
| TW200718700A (en) | Novel isoindole derivatives, compositions containing them, preparation thereof and pharmaceutical uses thereof, in particular as inhibitors of the activities of the HSP90 chaperone protein | |
| NO20064050L (no) | Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient | |
| SG143203A1 (en) | Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome | |
| JP2011068692A5 (enExample) | ||
| CN103655242B (zh) | 水解小麦蛋白洗发露 | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| CY1111257T1 (el) | Χρηση της αγομελατινης για τη ληψη φαρμακων προοριζομενων για τη θεραπεια των διπολικων διαταραχων | |
| JP2015509917A5 (enExample) | ||
| CL2007003216A1 (es) | Sal de 2(s), 4(s), 5(s), 7(s)-n-(3-amino-2,2-dimetil-3-oxo-propil)2,7-di(1-metil-etil)-4-hidroxi-5-amino-8-[4-metoxi-3-(3-metoxi-propoxi)fenil]-octanamida; proceso de preparacion; composicion farmaceutica; y uso para la profilaxis o tratamiento de en | |
| JP2008513348A5 (enExample) | ||
| CO6592037A2 (es) | Combinación de un aine y un aminoacido | |
| EA201201286A1 (ru) | Новое биологически активное соединение n-[3-(нитрофениламино)индол-2-илметилен]аминогуанидина гидрохлорид с противовоспалительной активностью | |
| NO20064048L (no) | Ny assosiasjon mellom agomelatin og en nordadrenalin-reopptaksinhibitor, og farmasoytiske sammensetninger inneholdende den |